Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27993946)

  • 1. Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome.
    Karagkounis G; Stranjalis G; Argyrakos T; Pantelaion V; Mastoris K; Rontogianni D; Komaitis S; Kalamatianos T; Sakas D; Tiniakos D
    J Clin Pathol; 2017 Jul; 70(7):593-599. PubMed ID: 27993946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.
    Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L
    Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and prognostic role of ALK in glioblastoma.
    Franceschi E; De Biase D; Di Nunno V; Pession A; Tosoni A; Gatto L; Tallini G; Visani M; Lodi R; Bartolini S; Brandes AA
    Pathol Res Pract; 2021 May; 221():153447. PubMed ID: 33887544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
    Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
    Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation.
    Chiba R; Akiya M; Hashimura M; Oguri Y; Inukai M; Hara A; Saegusa M
    PLoS One; 2017; 12(8):e0183516. PubMed ID: 28837676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GBM-associated mutations and altered protein expression are more common in young patients.
    Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
    Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.